American Society of Clinical Oncology Statement: Biosimilars in Oncology.

American Society of Clinical Oncology Statement: Biosimilars in Oncology.

J Clin Oncol. 2018 Feb 14;:JCO2017774893

Authors: Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, Zon R, Francisco M, Green S, Sherwood S, Harvey RD, Schilsky RL

Abstract
As many biosimilars come to market in the next several years, their use in oncology will play an important role in the future care of patients with cancer. ASCO is committed to providing education and guidance to the oncology community on the use of biosimilars in the cancer setting; therefore, ASCO has developed this statement to offer guidance in the following areas: (1) naming, labeling, and other regulatory considerations, (2) safety and efficacy of biosimilars, (3) interchangeability, switching, and substitution, (4) value of biosimilars, and (5) prescriber and patient education.

PMID: 29443651 [PubMed - as supplied by publisher]

http://ift.tt/2Cl5sVt